Harvard researchers investigating cannabis-based chemical to treat pancreatic cancer
A group of scientists from Harvard University’s Dana-Farber Cancer Institute recently released a cannabinoid-based study, published under the latest journal issue for Frontiers of Oncology.
In the report, researchers claim to have found evidence that a chemical, also known as a “flavonoid” (FBL- 03G), derived from cannabis may be capable of treating and extending the life expectancy for those with pancreatic cancer.
“The most significant conclusion is that tumor-targeted delivery of flavonoids, derived from cannabis, enabled both local and metastatic tumor cell kill, significantly increasing survival from pancreatic cancer. This has major significance, given that pancreatic cancer is particularly refractory to current therapies,” stated assistant researcher Wilfred Ngwa in an interview with Yahoo Lifestyle.
With the study still in its pre-clinical phase, all research has solely involved mice – but, with encouraging early results, researchers are hoping that human-trials could begin as early as 2021.
Medicinal Marijuana Program underway in Louisiana
Louisiana medical marijuana dispensaries aren’t reporting any problems or potential shortages.
Monday morning, state regulators in Louisiana released their first report on its MMJ program, which officially began selling product just two weeks ago.
In the report, regulators highlight a current patient-total sitting at just over 5,000 patients, but are forecasting that figure to reach 100,000-150,000 as soon as 2021; which will likely lead to a wave of new licenses. Currently, just 9 dispensaries, known as “medicinal marijuana pharmacies”, serve the whole state.
Louisiana is the first ‘deep-south’ state to legalize and sell medicinal cannabis, leading to neighboring states, like Mississippi, initiating their own ballot proposals to end prohibition.
Former NFL-superstar announces CTE-study
Calvin Johnson, the former Detroit Lions wide receiver and 6x Pro-Bowl selectee, recently announced a new partnership with Harvard University.
The partnership is designed to create a new wave of studies and research that intend to investigate the potential ways cannabis can be used to treat CTE – a progressive degenerative disease of the brain caused by severe head injuries and trauma. According to a 2017 study published by the New York Times, the degenerative disease was found in 110 of 111 NFL athletes, leading experts to call the ongoing CTE problem a “serious crisis.”
Using a $100,000 donation from Johnson, researchers “will do medical research for Primitive, run clinical trials related to CTE and pain and also will provide quality assurance from Harvard Medical School for any products the company creates.”
“What our mission is going to be is just to improve quality of life,” said Johnson’s business partner and ex-NFL lineman Rob Sims in an interview with ESPN.
Revolution announces expansion in Delavan
Thursday morning, in preparation for an expanding medicinal cannabis program and adult-use market, the Revolution held a groundbreaking ceremony adjacent to its cultivation facility in Delavan, Illinois.
The groundbreaking signals as the beginning of construction for ‘phase 4’, which is scheduled to be completed by June 2020. The new phase of construction and build-out will more than double Revolution’s existing cultivation production capacity, bringing its operational footprint to 150,000 sq. feet.
With the increase of operational and production capacity, the Revolution plans to nearly double its workforce, adding an estimated 60 new employment positions.
‘We’re very excited to bring additional housing, tax revenue and employment to the area”, said CEO Mark de Souza. “Without the city of Delavan being behind us in the strength that it is, we couldn’t be who we are today”
Other preparations have begun simultaneously to phase 4, including an additional expansion to the overall campus, which is set to add a new, 5,000 sq. feet connecting building that will serve as the new main-entrance.